"Thousands of cancer cells are loosely attached to primary tumor and are known to continuously detach and travel to other organs through peripheral blood flow. This process is the primary cause of spread of cancer into other organs and is called as 'metastasis', and is the actual cause of 90 per cent of deaths in cancer patients," lead scientists Jayant Khandare and Shashwat Banerjee said.
According to the Indian Council of Medical Research (ICMR), in India there will be more than 17 lakh new cases of cancer and over 8.8 lakh deaths are predicted in 2020, the duo told PTI.
"Conventional diagnostic approaches such as tumor biopsy are performed to determine the disease status. However, such invasive procedures are difficult and painful," Khandare said.
However, the detection and genetic characterisation of CTCs has been technically challenging due to their extremely low occurrence among billions of other blood cells, he said.
"In recent years, diverse diagnostic technologies have been evolving to meet the challenge of counting and isolating CTCs from patient blood samples," Khandare said.
Researchers from Maharashtra Institute of Pharmacy (MIP), Actorius Innovations and Research Pvt. Ltd. And Maharashtra Institute of Medical Education and Research Medical College, Pune designed 3-Dimensional microchannel system which can detect CTCs within a small blood sample, he said.
Their microfluidic system can detect, capture and remove the tumor cells from blood, making it potentially useful for both diagnosis and cancer treatment, Khandare said.
"There are plenty of clinical challenges to filter out CTCs from blood permanently thereby to reduce their burden in metastasis process and enhance cancer patient survival," Khandare and Banerjee said.
The duo's research has been published in international journal 'Advanced Materials Interface' as a cover page story, the first time AMI accorded the honour to a group of Indian researchers.
"This work is aimed at increasing cancer patients survival time by filtering out cancer cells that spread into secondary cancer by use of patient blood as in dialysis process," they said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
